Business · 25/09/2020
Lavipharm Laboratories, Inc. Proposes Withdrawal of FDA Approval for Five Abbreviated New Drug Applications
The FDA is proposing to withdraw approval of five ANDAs due to repeated failure to file required annual reports and implement approved risk evaluation and mitigation strategies.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →